Smith & Nephew SNATS Inc (SNN) — Quality & forensics
As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 73
- Quality 56
- Growth 45
- Balance sheet 55
- Cash quality 63
- Capital allocation 76
- Momentum 22
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the SNN chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-18
Quick answers
What is Smith & Nephew SNATS Inc's Closelook quality reading?
The composite reads 56/100 across 7 modules, as of 2026-09-18: valuation 73, quality 56, growth 45, balance sheet 55, cash quality 63, capital allocation 76, momentum 22. Closelook scores are research diary readings, not ratings or investment advice.
What is Smith & Nephew SNATS Inc's Altman Z-Score?
3.19, which sits in the safe zone (above 2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Smith & Nephew SNATS Inc's Piotroski F-Score?
7 of 9, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Smith & Nephew SNATS Inc's Beneish M-Score indicate?
-3.60 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- DXCM DexCom Incindustry
- SECT-B.ST Sectra AB (publ)industry
- SOON.SW Sonova H Agindustry
- CEVI.ST CellaVision ABindustry
- SYK Stryker Corporationindustry
- MOVE.SW Medacta Group SAindustry
- TXG 10X Genomics Incindustry
- BIO Bio-Rad Laboratories Incindustry
- BRKR Bruker Corporationindustry
- MDT Medtronic PLCindustry
- NVCR Novocure Ltdindustry
- EW Edwards Lifesciences Corpindustry
- ZBH Zimmer Biomet Holdings Incindustry
- CERS Cerus Corporationindustry
- GKOS Glaukos Corpindustry
- IART Integra LifeSciences Holdingsindustry
- PACB Pacific Biosciences of Californiaindustry
- PEN Penumbra Incindustry
- ABT Abbott Laboratoriesindustry
- GEHC GE HealthCare Technologies Inc.industry